In order to investigate whether SLC6A19 inhibition may be efficacious in patient populations with nonclassic PKU, dietary Phe intake was modulated in Pahenu2 mice to achieve varying severities of baseline plasma Phe. The gene discussed is SLC6A19; the disease is phenylketonuria.